Hydrogen gas inhalation alleviates oxidative stress in patients with post-cardiac arrest syndrome.
Tomoyoshi Tamura, Masaru Suzuki, Kei Hayashida, Yosuke Kobayashi, Joe Yoshizawa, Takayuki Shibusawa, Motoaki Sano, Shingo Hori, Junichi Sasaki · Journal of clinical biochemistry and nutrition · 2020
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In 5 patients, lPO slightly increased at 3 h after the initiation of H₂ gas inhalation but was then maintained over 24 h. These findings add human evidence that helps define the outcomes that did and did not change with molecular hydrogen in this study.
What the Findings Mean
H2HUBB reviewed how inhaled hydrogen gas affected the outcomes measured in 5 patients. LPO slightly increased at 3 h after the initiation of H₂ gas inhalation but was then maintained over 24 h.
What the Researchers Studied
The researchers studied 5 patients. The study used a human clinical study. The comparison condition was control condition or baseline measurements.
What Effects Did Molecular Hydrogen Have?
Source-reported hydrogen concentration: 2% source-reported H₂ gas concentration; Source-reported hydrogen exposure: 2% source-reported H₂ gas concentration. LPO slightly increased at 3 h after the initiation of H₂ gas inhalation but was then maintained over 24 h. The authors concluded that in the present study, the temporal changes in oxidative stress and inflammatory cytokines upon H₂ gas inhalation were sequentially measured in patients with PCAS. oxidative stress markers were reduced in cardiogenic post-CA patients but were slightly elevated in the patient with sepsis with H₂ gas inhalation.
Why These Findings Matter
This publication adds useful evidence about where molecular hydrogen did and did not change the measured outcomes, helping define the larger therapeutic evidence base.
How Strong Is This Evidence?
This is human clinical evidence from a human clinical study. H2HUBB interprets the findings in the context of the study design, sample, comparator, and measured outcomes rather than using one publication as a verdict on hydrogen therapy.
Technical Study Details
H2HUBB classifies this publication as human clinical study with human clinical evidence. The research population or model was 5 patients. The reported sample size was 3. The study used a human clinical study. The hydrogen delivery method was inhaled hydrogen gas. The source-reported hydrogen concentration was 2% source-reported H₂ gas concentration.
Limitations and Safety
Safety information: This was a sub-study of a single-center, open-label, single-arm, prospective intervention study, with the primary interest being the feasibility and safety of inhaled H₂ gas for patients with PCAS (Clinical trial identifier: UMIN000012381). ( 24 ) The study protocol was approved by the ethics committee of Keio University (Approval number: 20130075). Since this was a sub-study comprising a first-in-human PCAS study to evaluate the feasibility and safety of H₂ inhalation, it lacks a control group who did not inhale H₂.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.